Gilles De La Tourette syndrome. Clinical diagnostic and therapeutic features

Cover Page

Cite item

Full Text

Abstract

The article presents and analyzes current views on the classification, pathogenesis, diagnostic and treatment of Gilles de la Tourette syndrome. The age and gender features of the course of Tourette syndrome (TS) and comorbid disorders are described. In many psychiatrists’ opinion one of the most important courses is the study of psychiatric comorbidities in TS, which do not allow timely diagnosing of TS. Several authors propose to conceptualize certain comorbid disorders as independent ones that do not have common pathogenesis chains with TS. The least studied comorbid disorders in TS include epilepsy, although antiepileptic drugs can be effective in treating patients with TS. In consideration of the difficulty of TS diagnosing in the presence of psychiatric comorbidities, number of authors comes to the conclusion that patients have to get treatment of identified psychiatric disorder. However, according to the results of other authors’ clinical observations, there is evidence of aggravation of the course of both TS and comorbid disorder with the described therapeutic tactic. Genetics and instrumental research methods also do not reveal univocal diagnostics criteria. The authors of the article conclude that questions of diagnostics and treatment of Gilles de la Tourette syndrome are still unsolved

About the authors

Aleksandr G.  Sofronov

North-Western State Medical University named after
I.I. Mechnikov

Email: alex-sofronov@yandex.ru

Head of psychiatry and narcology department , professor, doctor of medical sciences, corresponding member of RAS 

Russian Federation, 191015, St. Petersburg, Kirochnaya str, 41

Dmitrij E. Zaytsev

D.E. Zaytsev Psychoneurological Center

Email: pnc-z@mail.ru

PhD, head physician

Russian Federation, 191040, 191040, St. Petersburg, Ligovsky pr., 50, letter Ф

Il’ya  D. Zaytsev

North-Western State Medical University named after
I.I. Mechnikov

Author for correspondence.
Email: dr.zaytsev.ilya@gmail.com

graduate student of psychiatry and narcology department in NWSMU n.a. I.I. Mechnikov, psychiatrist

Russian Federation, 191015, St. Petersburg, Kirochnaya str, 41

Nikolaj A. Titov

D.E. Zaytsev Psychoneurological Center

Email: titov_na@mail.ru

functional diagnostic doctor, neurologist 

Russian Federation, 191040, St. Petersburg, Ligovsky pr., 50, letter Ф

References

  1. Зайцев Д.Е. Синдром Жиля де ля Туретта: клинико-диагностические аспекты. Пособие для врачей. СПб.: Литография. 2012; 120 с. [Zaytsev D.E. Syndrom Gilya de la Turetta: klinico-diagnosticheskie i terapevticheskie aspekti. (Gilles de la Tourette syndrome: clinical diagnostic and therapeutic features.) St.Petersburg: Litoraphy. 2012; 120 p. (In Russ.)]
  2. American Psychiatric Association (2013). Diagnostic and manual of mental disorder (5th ed) (DSM-V). Washington, DC: APA. 2013; 81–83.
  3. Cavanna A.E. The Gilles de la Tourette syndrom — Quality of Life Scale for children and adolescents: Development and validation of the Italian version. Behav. Neurol. 2013; 27: 95–103.
  4. Itard J.M. Memoire sur quelques fontions involontaires des appareils de la locomotion de la prehension et de la voix. Arch. General Psychiatry. 1825; 8: 385–389.
  5. Ludolph A.G. Tourette syndrome and other tic disorders in childhood, adolescent and adulthood. Deutsches Arzteblatt International. 2012; 109 (48): 821–882.
  6. Gerasch S. Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome. Front. Neurosci. Child and Adolescent Psychiatry. 2016; 10: 416. DOI: http://doi.org/10.3389/fnins.2016.00416.
  7. Kompoloti K. Sources of disability in Tourette syndrome: children vs. adults. Tremor Other Hyperkinet. Mov. 2015; 5: 1–5. doi: 10.7916/D8Z60NQ2.
  8. Pauls D.L., Fernandez T.V., Mathews C.A. et al. The inheritance of Tourette disorder: a review. J. Obsessive Compulsive Related Dis. 2014; 3: 380–385.
  9. Robertson M.M. Attention deficit hyperactivity disorder, tics and Tourette’s syndrome: the relationship and treatment implications. A commentary. Eur. Child and Adolescent Psychiatry. 2006; 15: 1–11.
  10. Scharf J.M. Lack of association between SLITRK1var321 and Tourette syndrome in a large family based sample. Neurology. 2008; 70: 1495–1496.
  11. Martino D. Tourette syndrome. Neurosci. Behav. Rev. 2013; 37 (6): 1040–1049.
  12. Scharf J.M., Miller L.L., Gauvin C.A. et al. Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov. Dis. 2015; 30: 221–228.
  13. Debes N.M. Limited knowledge of Tourette syndrome causes delay of diagnosis. Neuropediatrics. 2008; 14: 101–105.
  14. Hirschtritt M.E. Child neurology: Diagnosis and treatment of Tourette syndrome. Am. Acad. Neurol. 2016; 87 (7): 65–67.
  15. Janik P., Kalbarczyk A., Sitek M. Clinical analysis of Gilles de la Tourette syndrome based on 126 cases. Neurologia i Neurochirurgia Polska. 2007; 41 (5): 381–387.
  16. Murray T.J. Tourettes’s syndrome: a treatable tic. Canadian Med. Assoc. J. 1978; 118: 1407–1410.
  17. Ханкевич Ю.Р. Предпосылки создания автомати-зированной информационной системы «паспорт здоровья спортсмена» с поддержкой базы данных. Актуал. пробл. физ. и спец. подготовки силовых структур. 2016; (1): 144–149. [Khankevich U.R. Prerequisites for the creation of an automated system “athletes’ health passport” with database support. Actual problems of physical and special training of power sructures. 2016; (1): 144–149. (Russ.)]
  18. Kobierska M. Coprolalia and Copropraxia in patients with Gilles de la Tourette syndrome. Neurologia i Neurochirurgia Polska. 2014; 48 (1): 1–7. DOI: http://doi.org/10/1016/j.pjnns.2013.03.001.
  19. Tanvi S., Jacubovski E., Muller-Vahl K.R. New insights into clinical characteristics of Gilles de la Tourette Syndrome: Findings in 1032 patients from a Single German Center. Front. Neurosci. 2016; 10: 415. doi: 10.3389/fnins.2016.00415. eCollection 2016.
  20. Valsamma E., Robertson M.M. Are there distinct subtypes in Tourette syndrome? Pure-Tourette syndrome versus Tourette syndrome-plus, and simple versus complex tics. Nueropsychiatric Dis. Treat. 2015; 11: 1431–1436. doi: 10.2147/NDT.S72284.
  21. Wanderer S. Relationship of obsessive-compulsive disorder to age-related comorbidity in children and adolescents with Tourette syndrome. J. Dev. Behav. Pediatrics. 2012; 33 (2): 124–133. doi: 10.1097/DBP.0b013e31823f6933.
  22. Lowe T.L., Capriotti M.R., McBurnett K. Long-term follow-up of patients with Tourette’s syndrome. Mov. Dis. Clin. Pract. 2018; 6 (1): 40–45. doi: 10.1002/mdc3.12696.
  23. Abelson J.F., Kwan K.Y., O’Roak B.J. et al. Sequence variants in SLITRK1 are associated with Tourette’s syndrome. Science. 2005; 310: 317–320.
  24. Stillman A., Biederman J., Harding M. et al. Developmentally reglated and evoluntionarily conserved expression of SLITRK1 in brain circuits implicated in Tourette syndrome. J. Comparative Neurol. 2009; 513: 21–37.
  25. Martino D., Ganos C., Worbe Y. Neuroimaging applications in Tourette’s syndrome. Intern. Rev. Neurobiol. 2018; 143: 65–108. doi: 10.1016/bs.irn.2018.09.008.
  26. Worbe Y. Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome. Brain: J. Neurol. 2015; 138: 472–482.
  27. Kim D.K. Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. Hum. Mol. Genet. 2006; 5: 3324–3328.
  28. Katayama K. SLITRK1-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalities. Mol. Psychiatry. 2010; 15: 177–184.
  29. Carter A.S., Social and emotional adjustment in children affected with Gilles de la Tourette’s syndrome: associations with ADHD and family functioning Attention deficit hyperactivity disorder. J. of Child Psychol. Psychiatry. 2000; 41: 215–223.
  30. Lombroso P., Scahill L. Tourette syndrome and obsessive-compulsive disorder. Brain Development. 2008; 30: 231–237.
  31. Hedderick E.F., Morris C.M., Singer H.S. A double-blind crossover study of Clonidine and Levetiracetam in Tourette syndrome. Pediatr. Neurol. 2009; 40: 420–425.
  32. Swedo S.E., Leonard H.L., Garvey M. et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am. J. Psychiatry. 1998; 155: 264–271.
  33. Wong L.C. Increased risk of epilepsy in children with Tourette syndrome: A population-based case-control study. Res. Dev. Disabil. 2016; 51–52: 181–187. DOI: DOI.org/10.1016/j.ridd.2015.10.005.
  34. Valsamma E., Snedden C., Crncec R. et al. Tourette syndrome, co-morbidities and quality of life. Australian & New Zealand Journal of Psychiatry. 2016; 50 (1): 82–93. doi: 10.1177/0004867415594429.
  35. Banaschewski T., Woerner W., Rothenberg A. Premonitory sensory phenomena and suppressibility of tics in Tourette syndrome: developmental aspects in children and adolescent. Dev. Med. Child Neurol. 2003; 45: 700–703.
  36. Cath D.C., Hedderly T., Ludolph A.G. et al. The ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur. Child and Adolescent Psychiatry. 2011; 20: 155–171.
  37. Groth C. Course of Tourette syndrome and comorbidities in a large prospective clinical study. J. Am. Acad. of Child & Adolescent Psychiatry. 2017; 56 (4): 304–312. doi: 10.1016/j/jaac/2017.01.010.
  38. Peterson B.S., Leckman J.F., Scahill L. Steroid hormones and Tourette’s syndrome: early experience with antiandrogen therapy. J. Clin. Psychopharmacol. 1994; 14: 131–135.
  39. Hirschtritt M.E. Lifetime prevalence, age of risk, and etiology of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry. 2015; 72 (4): 325–333. doi: 10.1001/jamapsychiatry.2014.2650.
  40. Chang K., Howe M., Gallelli K., Miklowitz D. Prevention of pediatric bipolar disorder: integration of neurobiological and psychosocial processes. Ann. New York Acad. Sci. 2006; 1094: 235–247.
  41. Johnco C. Suicidal ideation in youth with tic disorders. J. Affect. Dis. 2016; 200: 204–211. doi: 10.1016/j.jad.2016.04.027.
  42. Kerbeshian J. Tourette syndrome and comorbid early-onset schizophrenia. J. Psychosomat. Res. 2009; 67 (6): 515–523. DOI: http://dx.doi.org/10.1016/j.jpsychores.2009.08.002.
  43. Piedad J.C. Depression in Tourette syndrome: A controlled and comparison study. J. Neurol. Sci. 2016; 364: 128–132. DOI: http://dx.doi.org/10.1016/j.jns.2016.03.030.
  44. Spencer T., Biederman J., Harding M. et al. The relationship between tic disorder and Tourette’s syndrome revisited. J. Am. Acad. of Child and Adolescent Psychiatry. 1995; 34: 1133–1139.
  45. Ghosh D. Sleep disorders in children with Tourette syndrome. Pediatric Neurol. 2014; 51 (1): 31–35. DOI: http://dx.doi.org/10.1016/j.pediatrneurol.2014.03.017.
  46. Berthier M.L., Kulisevsky J., Campos V.M. Bipolar disorder in adult patients with Tourette’s syndrome: a clinical study. Biol. Psychiatry. 1998; 43: 364–370.
  47. Rizzo R. Gilles de la Tourette syndrome, depression, depressive illness, and correlates in a child and adolescent population. J. Child and Adolescent Psychopharmacol. 2017; 27 (3): 243–249. doi: 10.1089/cap.2016.0120.
  48. Storch E.A., Hanks C.E., Mink J.W. et al. Suicidal thoughts and behaviors in children and adolescent with chronic tic disorder. Depression and Anxiety. 2015; 32 (10): 744–753. doi: 10.1002/da.22357.
  49. Termine C. Emerging treatment strategies in Tourette syndrome: What’s in the pipeline? Intern. Rev. Neurobiol. 2013; 112 (1): 445–480. DOI: http://doi.org/10/1016/B978-0-12-411546-0.00015-9.
  50. Roessner V., Plessen K.J., Rothenberg A. et al. European clinical guidelines for Tourette syndrome and other tics disorders. Part II: pharmacological treatment. Eur. Child And Adolescent Psychiatry. 2011; 20: 173–196.
  51. Calarge C.A., Ivins S.D., Motyl K.J. et al. Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents. Therap. Adv. Psychopharmacol. 2013; 3: 278–293.
  52. Rath J.G. Antipsychotic-induced hyperprolactinemia in Tourette syndrome. Therap. Adv. Psychopharmacol. 2017; 7 (6): 201–205. doi: 10.1177/2045125317705012.
  53. Salle F. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette’s disorder in children and adolescents. J. Child and Adolescent Psychopharmacol. 2017; 27 (9): 771–781. DOI: http://doi.org/10.1089/cap.2016.0026.
  54. Shim S.H. Adolescent with Tourette syndrome and bipolar disorder: a case report. Clin. Psychopharmacol. Neurosci. 2014; 12 (3): 235–239. DOI: http://dx.doi.org/10/9758/cpn.2014.12.3.235.
  55. Zhang X.H. Deep brain stimulation of the globus pallidus internus in patients with intractable Tourette syndrome: A 1-year follow-up study. Chinese Med. J. 2016; 129 (9): 1022–1027. doi: 10.4103/0366-6999.180512.
  56. Rizzo R., Gulisano M. Clinical pharmacology of comorbid attention deficit hyperactivity disorder in Tourette syndrome. Intern. Rev. Neurobiol. 2013; 112: 415–444. DOI: http://doi.org/10.1016/B978-0-12-411546-0.00014-7.
  57. Niemann N., Jankovich J. Real-world experience with VMAT2 inhibitors. Clin. Neuropharmacol. 2019; 42 (2): 37–41. doi: 10.1097/WNF.0000000000000326.
  58. Muller-Vahl K.R. Treatment of Tourette syndrome with cannabinoids. Behav. Neurol. 2013; 27 (1): 119–124. doi: 10.3233/BEN-120276.
  59. Coulombe M.A., Elkaim L.M., Alotaibi N.M. et al. Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: meta-analysis with individual participant data. J. Neurosurg. Pediatrics. 2018; 1: 1–11. doi: 10.3171/2018.7.PEDS18300.
  60. Roth J. The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies. Parkinsonism and Related Dis. 2018; 46 (1): 75–79. DOI: http://dx.doi.org/10.1016/ j.parkreldis.2017.08.004.
  61. O’Hare D., Helmes E., Valsamma E. et al. The impact of tic severity, comorbidity and peer attachmentt on quality of life outcomes and functioning in Tourette’s syndrome: Parental perspectives. Child Psychiatry & Human Development. 2016; 47 (4): 563–573.
  62. Curtis-Wendlandt L. Treating Tourette syndrome without drugs. J. Pediatr. Child Health. 2019; 55 (3): 367–368. doi: 10.1111/jpc.14351.

Copyright (c) 2020 Sofronov A.G., Zaytsev D.E., Zaytsev I.D., Titov N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies